Siemens medical technology sales down 13% in first half:
This article was originally published in Clinica
Medtech remains one of Siemens problems as other parts of the German conglomerate's business have shown strong growth in the first half of fiscal 1995 to the end of March. Medtech reported a 13% decline in first-half sales to DM 3,200 million ($2,336 million). New orders fell 12% compared with the previous year. Siemens' group turnover, on the other hand, rose 5% to DM 40,000 million, with all growth coming from domestic business at a time when international sales were dampened by the strong German mark. Net income increased 7% to DM 939 million. Siemens warns that the appreciation of the mark could thwart the company's aim to increase profits by 20% in fiscal 1995.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.